Eli Lilly | LLY - Cash And Equivalent



Eli Lilly reported $3.38B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Abbott USD 6.95B 419M Jun/2025
ALKERMES USD 521.2M 121.39M Jun/2025
Amgen USD 8.03B 782M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Drreddys Laboratories INR 9B 7.91B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Medtronic USD 2.22B 978M Apr/2025
Merck USD 8.01B 622M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Novartis USD 6.66B 4.8B Jun/2025
Novo Nordisk A/S 18.44B 5.78B Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Prestige Brands USD 139.5M 41.62M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
Sanofi 15.36B 7.92B Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025
Zoetis USD 1.44B 286M Jun/2025